Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin - Wikidata - awgldk - TriplyDB

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin

http://www.wikidata.org/entity/Q34018372

about

Progress toward overcoming hypoxia-induced resistance to solid tumor therapy Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update Pharmacological induction of the 70-kDa heat shock protein protects against brain injury A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.In pursuit of new anti-angiogenic therapies for cancer treatment Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010).Molecular-targeted agents combination therapy for cancer: developments and potentials.Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).Tanespimycin and tipifarnib exhibit synergism in inducing apoptosis in melanoma cell lines from later stages of tumor progression.Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia.Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

P2860

Q26796405-0418F9DD-C751-48FB-9EF6-E2F0F6747BB6 Q27022514-FC3D6448-94B1-4F5D-8689-F2B26CEA6830 Q28272905-28A61F3F-93D6-4A16-9A1B-BA14D0169418 Q34758221-6759CCCF-7ABA-40A6-997A-6134D84B9810 Q35691439-970568B4-16B1-4415-83F4-5D2FA40A331F Q35979667-DF9059E3-B04E-4A05-BB72-933C0D18413A Q36270115-312291FF-973E-4A8D-8531-D3FA75DBA4C8 Q36556257-E262D0E4-B6E5-4D3D-B719-BAE71AEA2D82 Q37825180-FB344CA2-6BBE-4BBA-A3B9-7B0F673821AD Q37826426-AFA0D30D-6876-46A1-959E-8BB04EEAD87B Q38104670-6EFC07B2-11D7-4DE6-A401-FD51C60FCD0C Q38219616-44E4DEEB-E73E-4221-8E36-A917FAA6DF96 Q39091969-005DFB61-46EA-4220-8822-E5CA6C6FA91B Q40297530-FF02DB7E-33C8-4F71-A4C3-A0A8C512ED07 Q41661254-A92A9805-163B-4030-AB3D-0BF05CF47242 Q43841175-0B2AFEEE-1521-4DE5-8E77-C403687D0AE4

P2860

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin

http://www.wikidata.org/entity/Q34018372

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Safety, efficacy, pharmacokine ...... of sorafenib and tanespimycin

@ast

Safety, efficacy, pharmacokine ...... of sorafenib and tanespimycin

@en

Safety, efficacy, pharmacokine ...... of sorafenib and tanespimycin

@nl

type

label

Safety, efficacy, pharmacokine ...... of sorafenib and tanespimycin

@ast

Safety, efficacy, pharmacokine ...... of sorafenib and tanespimycin

@en

Safety, efficacy, pharmacokine ...... of sorafenib and tanespimycin

@nl

prefLabel

Safety, efficacy, pharmacokine ...... of sorafenib and tanespimycin

@ast

Safety, efficacy, pharmacokine ...... of sorafenib and tanespimycin

@en

Safety, efficacy, pharmacokine ...... of sorafenib and tanespimycin

@nl

P1433

Q34018372-39C87114-E805-4C04-8AB7-38DE9984CE9C

P1476

Q34018372-0FEF3144-F86E-4FBD-BE7D-5C93B726D421

P2093

Q34018372-1D400986-F484-4D89-B2A7-27188E720156

Q34018372-362C08A3-56B5-4B5C-AC5C-C506EDB897F4

Q34018372-3F0DC055-E860-49A1-AA0D-ABE14112FD0C

Q34018372-4EA73AFD-F3AF-441B-B51E-E39B49BC797D

Q34018372-67F516AF-43E0-4762-9D6C-C54AE05E6CA7

Q34018372-87CC422F-597A-4AB4-A161-839A5DB359A4

Q34018372-9287C588-0481-4289-B1D9-4540C72B0D1D

Q34018372-F6333509-9958-401A-A76D-3C6175F76CD0

Q34018372-F7B63C9C-0604-4CF9-8319-CD6A915A8CE1

Q34018372-F806B2DA-54A6-4151-B38D-3758571BD8B1

P2860

Q34018372-0E15087D-88CA-4B6D-9EEE-8D03718FB93C

Q34018372-17FF0FA5-6038-48A7-A8BC-77EED9696FD4

Q34018372-22576E24-88D1-442C-A1D4-5394AACF5692

Q34018372-2BC6D1C8-2B32-4437-A005-75DB03D41563

Q34018372-30A530A7-85EF-4E8D-9931-84E9E956F94E

Q34018372-37ED44A6-7CBD-4C9C-856D-8C2E2F35E544

Q34018372-38C7CB6D-9558-4DC6-8DC6-46C1CB882FB4

Q34018372-48B39DA7-823D-448F-866B-5E4FE19F7BD3

Q34018372-4BA7DFCA-9653-47C1-B735-653519F1EB12

Q34018372-4C079C6C-7181-4473-B69E-12AAE4D62314

P304

Q34018372-A171CDF0-4048-40E0-B7DF-50172E281E77

P31

Q34018372-7438EE5B-5902-417F-948A-4CE30C48F848

P356

Q34018372-A382E53F-738E-4FE3-80AF-80D39670F059

P407

Q34018372-BB15B88A-146A-4EB6-9DB3-A12708D8AC39

P433

Q34018372-3D58D24F-CC17-41FA-A870-CDECEF241121

P478

Q34018372-79CEEBA0-0EB9-45D4-8D9D-484EB994912A

P577

Q34018372-043CA767-459B-4597-A08D-60D1A114B7AE

P698

Q34018372-50DDE1A9-442C-4865-98D3-0B0CEA390AF6

P932

Q34018372-A3F46366-9F38-490C-9652-F09D033D5CDC

P356

1078-0432.CCR-10-0503

P1433

Clinical Cancer Research

P1476

Safety, efficacy, pharmacokine ...... of sorafenib and tanespimycin

@en

P2093

Angelika M Burger

http://www.w3.org/2001/XMLSchema#string

Edward A Sausville

http://www.w3.org/2001/XMLSchema#string

Jing Li

http://www.w3.org/2001/XMLSchema#string

Lance K Heilbrun

http://www.w3.org/2001/XMLSchema#string

M Naomi Horiba

http://www.w3.org/2001/XMLSchema#string

Merrill J Egorin

http://www.w3.org/2001/XMLSchema#string

Patricia M Lorusso

http://www.w3.org/2001/XMLSchema#string

Percy Ivy

http://www.w3.org/2001/XMLSchema#string

Simon Pacey

http://www.w3.org/2001/XMLSchema#string

Ulka N Vaishampayan

http://www.w3.org/2001/XMLSchema#string

P2860

Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation

Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent

Mutations of the BRAF gene in human cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

Sorafenib in advanced clear-cell renal-cell carcinoma

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

P304

3795-3804

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-0503

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20525756

http://www.w3.org/2001/XMLSchema#string

P932

2909581

http://www.w3.org/2001/XMLSchema#string